Status:

UNKNOWN

Effect of Meal Timing in T2D on Hepatocytes SRIT1 and Clock Genes

Lead Sponsor:

Tel Aviv University

Conditions:

Type 2 Diabetes

Obesity

Eligibility:

All Genders

30-70 years

Phase:

NA

Brief Summary

This study is undertaken to explore in T2D, the effect of meal timing on serum induced SIRT1 and Clock Genes mRNA expression in cultured hepatocytes. Fasting serum samples were collected from T2D part...

Detailed Description

The timing of many physiological processes, including glucose metabolism, is coordinated by the circadian clock gene system. The circadian clock regulation, optimize glucose metabolism for the consump...

Eligibility Criteria

Inclusion

  • T2D patients with stable treatment for at least 3 month preceding the study.
  • HgA1c \>7.5 %.
  • Age \> 30 years.
  • BMI: 27-34 kg/m2.
  • Treatment with antidiabetic drugs (i.e. metformin, DPP4 inhibitors, glinides) and GLP-1 analogs, will be allowed
  • Anti-hypertensive treatment will be allowed.
  • Lipid-lowering medication also allowed

Exclusion

  • Type 1 diabetes.
  • Major illnesses (liver, heart, kidney, infectious, neurological, psychiatric, immunological, active malignancy).
  • Change in weight of \> 4.5 kg within 3 month prior the diet onset.
  • Night or rotating shift workers.
  • Those who crossed more than 2 time zones during 2-week period prior to study onset.

Key Trial Info

Start Date :

May 31 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 20 2020

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT04405895

Start Date

May 31 2020

End Date

October 20 2020

Last Update

May 28 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Wolfson Medical Center

Holon, Please Select, Israel, 58100